Incyte will bring its latest PD-1 data in anal cancer and lung cancer to the FDA, but whether the agency will accept them for evaluation remains to be seen ...
Incyte’s late PD-1 entrant Zynyz has chalked up a unique clinical win. Yet company CEO Hervé Hoppenot views the antibody molecule not necessarily as a major revenue driver but as an aide to the ...
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced that multiple abstracts featuring new data from its oncology portfolio will be presented at the 2025 American Society of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results